Rheumatology

• Adult-Onset Still’s Disease (AOSD) and sJIA

  These autoinflammatory syndromes respond well to: IL-1 inhibitors (anakinra, canakinumab) IL-6 inhibitors (tocilizumab)

• Behcet’s Disease

  Behcet’s disease is a rare, chronic, multisystem vasculitis characterized by recurrent oral and genital ulcers, uveitis, skin lesions, and vascular, neurologic, and gastrointestinal involvement. Disease manifestations ar...

• Psoriatic Arthritis & Ankylosing Spondylitis

  These spondyloarthropathies benefit from: IL-17 inhibitors (secukinumab, ixekizumab) IL-23 inhibitors (guselkumab, risankizumab) TNF blockade remains foundational for axial disease

• Relapsing Polychondritis

  Relapsing polychondritis is a rare autoimmune disease characterized by recurrent inflammation and progressive destruction of cartilaginous structures, most commonly affecting the ears, nose, tracheobronchial tree, and jo...

• Rheumatoid Arthritis (RA)

  Early aggressive treatment guided by treat-to-target strategies has significantly reduced disability.

• Systemic Lupus Erythematosus (SLE)

  Research is now focused on organ-specific lupus (e.g., lupus nephritis) and precisionimmunology.

• Systemic Sclerosis (Scleroderma)

  A disease marked by fibrosis and vascular injury, systemic sclerosis remains difficult to treat.

• Vasculitis

  These approaches reduce steroid toxicity while maintaining disease control.